Depression, Anxiety, Psychotraumatism and Suicide: From bench to bedside and general population

Depression, anxiety, psychotrauma and suicide are major public health priorities, that are intricated.

The MOODS project aims at decreasing suffering, disability, mortality and costs due to depression, anxiety, psychotrauma and suicide. This project is a major public health research challenge.

Our objective is to improve the comprehension, prevention and treatment of depression, anxiety, psychotrauma and suicide, through an inter-disciplinary approach, that could identify adequate phenotypes, relevant biomarkers and therapeutic strategies in this field, with a special focus on age and gender.

To address these aims, we will take advantage of tools and experience developed by the pre-clinical, clinical and general population components of the team: animal models, pre-existing cohorts of depressed patients and pre-existing cohorts of the CESP.

Lire la suite

The MOODS team is a multidisciplinary team with preclinical (neurosciences, pharmacology), clinical (psychiatry, child psychiatry, psychology, pharmacology, geriatry), anthropology, epidemiology and public health expertises.

The MOODS team comprises 70 members, of whom 14 PU, 17 HDR, 4 MCU, 1 INSERM CR and 1 ingeneer.

The team is affiliated to Paris- Saclay University (Faculty of Medicine and Faculty of Pharmacy), Antilles University and La Réunion University, and also to Paris-Saclay University-Hospital Group, Assistance Publique des Hôpitaux de Paris, to Martinique University-Hospital Center and To La Reunion University-Hospital Center.


Hôpital du Kremlin Bicêtre, Bat. Lasjaunias

Porte 76

84 rue du Gl Leclerc
94276 Le Kremlin Bicêtre

To visit

Laboratoire de Neuropharmacologie Faculté de Pharmacie, Université Paris Sud

Tour D1, 2e étage F

5, rue J-B Clement,
92296 Chatenay-Malabry

To visit

Principaux Financeurs
Université Paris-Sud
ANR (Agence nationale de la Recherche)


Dernières publications

Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case–control study. Dragos Ciocan, Anne-Marie Cassard, Laurent Becquemont et al. . 2021; :
The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment. Romain Colle, Khalil El Asmar , Céline Verstuyft, Pierre-Marie Lledo, Françoise Lazarini, Kenneth Chappell, Eric Deflesselle, Abd El Kader Ait Tayeb, Bruno Falissard, Emmanuelle Duron, Samuel Rotenberg, Jean-Francois Costemale-Lacoste, Denis J David, Florence Gressier, Alain M Gardier, Thomas Hummel, Laurent Becquemont, Emmanuelle Corruble . Psychol Med .. 2020; : . doi:10.1017/S0033291720003918
Hospitalization for self-harm during the early months of the Covid-19 pandemic in France: a nationwide study. Fabrice Jollant, Adrien Roussot, Emmanuelle Corruble, Jean-Christophe Chauvet-Gelinier, Bruno Falissard, Yann Mikaeloff, Catherine Quantin. MedRxiv. 2020; : . doi:10.1101/2020.12.18.20248480
Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Briana K Chen, Victor M Luna, Christina T LaGamma, Xiaoming Xu, Shi-Xian Deng, Raymond F Suckow, Thomas B Cooper, Abhishek Shah, Rebecca A Brachman, Indira Mendez-David, Denis J David, Alain M Gardier, Donald W Landry, Christine A Denny . . 2020; : . doi: 10.1038/s41386-020-0714-z
Non-presentation at hospital following a suicide attempt: a national survey. Fabrice Jollant, Keith Hawton, Guillaume Vaiva, Christine Chan-Chee, Enguerrand du Roscoat and Christophe Leon. Psychological Medicine. 2020; : . doi:10.1017 / S0033291720002305